



黄冈师范学院
HUANGGANG NORMAL UNIVERSITY



THE HONG KONG
POLYTECHNIC UNIVERSITY
香港理工大学

Do potential predatory journals and mainstream ones differ in handling retractions?

(work in progress)

Shaoxiong Brian Xu, Tingyu Liu, Hassan Nejadghanbar, Guangwei Hu

Hong Kong Polytechnic University
Huanggang Normal University

June 5, 2024



Journal Quality Control

- Pre-publication: peer review
- Post-publication: correction + **retraction**

Journal classification by quality

- Legitimate journals > Potential predatory journals (PPJs) > Predatory journals.
- Various characteristics identified are used as criteria for defining PPJs.
- Predatory journals are criticized for/defined by their lack of (rigorous) peer review.
- Journal performance in retraction handling can be utilized as an additional criterion for identifying PPJs.

Beall's List

of Potential Predatory Journals (PPJs) and Publishers (PPPs)

<https://beallist.net/>

- Curated by Jeffrey Beall, a former librarian at the University of Colorado Denver.
- Criticized for the unreliability and subjectivity of its inclusion criteria.
- Suspended in January 2017.
- Revived and updated by an anonymous researcher.
- Data coverage: **1,511** stand-alone PPJs + 1,327 PPPs.

Research objectives

- To identify retractions by the standalone PPJs on the updated Beall's List.
- To develop a framework for assessing journal performance in retraction handling.
- To assess the PPJs' performance in retraction handling.
- To compare retraction-handling performance between PPJs and legitimate ones (?)

BEALL'S LIST

OF POTENTIAL PREDATORY JOURNALS AND PUBLISHERS

- PUBLISHERS
- STANDALONE JOURNALS
- VANITY PRESS
- CONTACT
- OTHER

Potential predatory scholarly open-access publishers

Instructions: first, find the journal's publisher – it is usually written at the bottom of the journal's webpage or in the "About" section. Then simply enter the publisher's name or its URL in the search box above. If the journal does not have a publisher use the Standalone Journals list.

All journals published by a predatory publisher are potentially predatory unless stated otherwise.

Original list

This is an archived version of the Beall's list – a list of potential predatory publishers created by a librarian Jeffrey Beall. We will only update links and add notes to this list.

- 1088 Email Press
- 2425 Publishers
- The 5th Publisher
- ABC Journals
- A M Publishers
- Abhinav
- Academe Research Journals
- Academia Publishing
- Academia Research
- Academia Scholarly Journals (ASJ)
- Academic and Business Research Institute

Useful pages

- List of journals falsely claiming to be indexed by DOAJ
- DOAJ: Journals added and removed
- Nonrecommended medical periodicals
- Retraction Watch
- Flaky Academic Journals Blog
- List of scholarly publishing stings

Conferences

- Questionable conferences [archive]
- How to avoid predatory conferences
- Flaky Academic Conferences Blog

[GO TO UPDATE](#)

❖ Framework for assessing journal performance in retraction handling (COPE Council, 2019; NISO, 2023; Oransky, 2015; Xu & Hu, 2021, 2023, 2024).

- 34 unique indicators
- 6 primary + 16 secondary + 16 tertiary indicators

❖ Key findings

• PPJ retractions

- 645 retractions by 45 PPJs as archived by the RWDB.
- Rate of retracting PPJs: 3.0% ($45 \times 100 / 1,511$).

• Silent retraction rate

- 145 publications retracted with a retraction notice;
- Silent retraction rate: 77.% ($((645-145) \times 100 / 645)$).

• Overall **poor** PPJ performance in retraction handling

- 90-100%: 7 in green
- 80-90%: 4 in blue
- 60-70%: 1 in orange
- 50-60%: 5 indicators in brown
- < 50%: 17

• Changes over time

- 645 retractions documented by RWDB as of 2022;
- 420 retractions located in January 2024 ;
- 414 retractions located in May 2025;
- Performance **decline** in the first 8 indicators.

Indicators of journal performance in retraction handling	2024/01		2024/05	
	f	%	f	%
1. Availability of a retraction policy (<i>N</i> = 45)	26	57.8	24	53.3
2. Accessibility of the retracted publication (<i>N</i> = 645)	420	65.1	414	64.2
3. Accessibility of the retraction notice (<i>N</i> = 645)	145	22.5	137	21.2
4. Connectivity between the two corresponding documents (<i>N</i> =645)	106	16.4	96	14.9
5. Retraction visibility (<i>N</i> = 645)				
5.1 The retraction notice title indicating retraction	142	22.0	134	20.8
5.2 The retraction notice being available in PDF format	139	21.6	131	20.3
5.3 One retraction notice for one retracted publication	136	21.1	135	20.9
5.4 The retracted publication being watermarked	109	16.9	101	15.7
5.5 The HTML of the retraction notice enabling sharing	89	13.8	89	13.8
6. Informativeness of the retraction notice in PDF format (<i>N</i> =139)				
6.1 Bibliographic information of the retraction notice				
6.1.1 Journal title	130	93.5		
6.1.2 Volume, issue, and page	128	92.1		
6.1.3 Title	123	88.5		
6.1.4 Publication date	123	88.5		
6.1.5 Publisher name	81	58.3		
6.1.6 DOI	81	58.3		
6.1.7 Author name(s)	12	8.6		
6.1.8 Author affiliation(s)	1	0.7		
6.2 Bibliographic information of the retracted publication				
6.2.1 Title	138	99.3		
6.2.2 Journal title	134	96.4		
6.2.3 Author name(s)	134	96.4		
6.2.4 Publication date	131	94.2		
6.2.5 Volume, issue, and page	130	93.5		
6.2.6 Publisher name	81	58.3		
6.2.7 DOI	37	26.6		
6.2.8 Author affiliation(s)	33	23.7		
6.3 Retraction reason(s)	124	89.2		
6.4 Indication of agents of key acts	113	81.3		
6.5 Allegation(s) against the retracted publication	79	56.8		
6.6 Investigation(s) into the allegation(s)	75	54.0		
6.7 Act of performing retraction	73	52.5		
6.8 Request for retraction	66	47.5		
6.9 Announcement of retraction	63	45.3		
6.10 Indication of availability of the retracted publication	53	38.1		
6.11 Indication of time points of key acts	11	7.9		

- *International Journal of Nanomedicine* ($n = 50$) and *Oncotarget* ($n = 25$), accounting for 52% of the 145 retraction notices available for analysis.
- The 2 PPJs included in **SCIE** remarkably outperformed other PPJs in retraction handling.
- *Journal of Fundamental and Applied Sciences* ($n = 420$ silent retractions) and *International Journal of Electrochemical Science* ($n = 24$)
- The reliability of Beall's List of standalone PPJs is questioned in terms of some PPJs' outstanding performance in retraction handling.
- Journal performance in retraction handling should be considered as an additional journal selection criterion of Web of Science Core Collection.
- Journal quality can be dynamic, and legitimate journals, even prestigious ones, may not outperform some so-called PPJs in retraction handling.

RETRACTION

Fabrication and Characterization of Gimepiride Nanosuspension by Ultrasonication-Assisted Precipitation for Improvement of Oral Bioavailability and in vitro α -Glucosidase Inhibition [Retraction]

Fulltext Metrics Get Permission Cite this article

Authors [Rahim H.](#), [Sadiq A. Khan S.](#), [Amin F. Vilas S. Shahar A.S.](#), [Mahmood H.H.](#)

Received 23 November 2022

Accepted for publication 23 November 2022

Published 28 November 2022 Volume 2022:17 Pages 5779–5780

DOI <https://doi.org/10.2147/IJN.S398841>

Download Article [PDF]


Rahim H, Sadiq A, Khan S, et al. *Int J Nanomedicine*. 2019;14:6287-6296.

The Editor and Publisher of *International Journal of Nanomedicine* wish to retract the published article. Concerns were raised about the alleged duplication of regions within the image used in Figure 4A. The authors did respond to our queries but were unable to provide a satisfactory explanation for the alleged duplication. In addition, further analysis of the original image used in Figure 4A indicates that regions within the image may have been altered. The Editor determined that the findings reported in the article were unreliable and requested for the article to be retracted. The authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

This retraction relates to this paper

 © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the [Creative Commons Attribution - Non-Commercial License \(CC BY-NC 4.0\)](https://creativecommons.org/licenses/by/4.0/). By accessing the work you hereby accept the Terms. Non-commercial use of the work is permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our [terms](https://www.dovepress.com/terms.php).

International Journal of Nanomedicine Dovepress

ORIGINAL RESEARCH

RETRACTED ARTICLE: Fabrication and characterization of gimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α -glucosidase inhibition

This article was published in the following Dove Press journal: *International Journal of Nanomedicine*

Haroon Rahim¹, Abdul Sadiq²⁻⁴, Shahzeb Khan²⁻⁴, Fazil Amin¹, Abdaleay A Shahaz^{5,6}, Hafiz Majid Mahmood⁷

¹Department of Pharmacy, Sindh University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan; ²Department of Pharmacy, University of Malakand, Chakdara, Khyber Pakhtunkhwa, 18000, Pakistan; ³Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, 4000, South Africa; ⁴Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA; ⁵Department of Pharmacy, King Fahd University of Petroleum & Minerals, Dhahran, 31261, Saudi Arabia; ⁶Physicochemical Research Center, King Fahd University of Petroleum & Minerals, Dhahran, 31261, Saudi Arabia; ⁷Department of Pharmacy, Sindh University, Riyadh 11451, Saudi Arabia

Purpose: We aimed to enhance the solubility, dissolution, oral bioavailability, and α -glucosidase inhibition of gimepiride (Gim) by fabricating its nanosuspension using a precipitation-ultrasonication approach.

Methods: Gim nanosuspensions were fabricated using optimized processing conditions. Characterization of Gim was performed using Microm Zetasizer, scanning electron microscopy, transmission electron microscopy, differential scanning calorimetry, and powder X-ray diffraction. Minimum particle size and polydispersity index (PDI) values were found to be 152.4±2.42 nm and 0.23, respectively, using hydroxypropyl methylcellulose: 6.48%, 1% w/v, polyvinylpyrrolidone K30: 1% w/v, and sodium lauryl sulfate: 0.12% w/v, keeping ultrasonication power fixed at 100 W, with 15 minutes' processing at 3-second pauses. In vivo oral bioavailability was assessed using rabbits as a model.

Results: The in vitro solubility of the Gim nanosuspensions was substantially enhanced 3.14- and 5.14-fold compared to unprocessed drug in stabilizer solution and unprocessed active pharmaceutical ingredient. Also, the dissolution rate of the nanosuspensions was substantially boosted when compared to the marketed formulation and unprocessed drug candidate. The results showed that 97.1% of Gim nanosuspensions dissolved in the first 10 minutes compared to 10.17% of processed Gim, 42.19% of microsuspensions, and 19.94% of marketed tablets. In vivo studies conducted in animals, i.e. rabbits, demonstrated that maximum concentration and AUC₀₋₂₄ with oral dosing were twofold (5 mg/kg) and 1.74-fold (2.5 mg/kg) and 1.80-fold (5 mg/kg) and 1.63-fold (2.5 mg/kg), respectively, and compared with the unprocessed drug formulation. In vitro α -glucosidase inhibition results showed that fabricated nanosuspensions had a pronounced effect compared to unprocessed drug.

Conclusion: The optimized batch fabricated by ultrasonication-assisted precipitation can be useful in boosting oral bioavailability, which may be accredited to enhanced solubility and dissolution rate of Gim, ultimately resulting in its faster rate of absorption due to nanonization.

Keywords: gimepiride nanosuspension, precipitation-ultrasonication approach, boosted bioavailability

Introduction

It has been observed that many active pharmaceutical ingredients (APIs) display low aqueous solubility and bioavailability during the drug-development stage.¹ Recently, nanosuspension has been successfully fabricated to overcome

Correspondence: Haroon Rahim, Department of Pharmacy, Sindh University of Science and Information Technology, Peshawar, Peshawar 25000, Khyber Pakhtunkhwa, Pakistan. Tel +92 332 946 1462. Email hrahim@du.edu.pk

© 2022 Haroon et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the [Creative Commons Attribution - Non-Commercial License \(CC BY-NC 4.0\)](https://creativecommons.org/licenses/by/4.0/). By accessing the work you hereby accept the Terms. Non-commercial use of the work is permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our [terms](https://www.dovepress.com/terms.php).

International Journal of Nanomedicine Dovepress

RETRACTION

Fabrication and Characterization of Gimepiride Nanosuspension by Ultrasonication-Assisted Precipitation for Improvement of Oral Bioavailability and in vitro α -Glucosidase Inhibition [Retraction]

Rahim H, Sadiq A, Khan S, et al. *Int J Nanomedicine*. 2019;14:6287-6296.

The Editor and Publisher of *International Journal of Nanomedicine* wish to retract the published article. Concerns were raised about the alleged duplication of regions within the image used in Figure 4A. The authors did respond to our queries but were unable to provide a satisfactory explanation for the alleged duplication. In addition, further analysis of the original image used in Figure 4A indicates that regions within the image may have been altered. The Editor determined that the findings reported in the article were unreliable and requested for the article to be retracted. The authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

International Journal of Nanomedicine Dovepress

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnosis, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, Medline, CAS, SciSearch®, Current Contents™, Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Received 23 November 2022
Accepted 23 November 2022
Published 28 November 2022

International Journal of Nanomedicine 2022:17 5779

Retractions

A Retraction will be issued where a major error (e.g., in the methods or analysis) invalidates the conclusions in the article, or where it appears research or publication misconduct has taken place (e.g., research without required ethical approvals, fabricated data, manipulated images, plagiarism, duplicate publication, etc.).

The decision to retract an article will be made in accordance with both Dove Medical Press policies and COPE guidelines. The decision will follow a full investigation by Dove Medical Press editorial staff in collaboration with the journal's editorial team. Authors and institutions may request a retraction of their articles if they believe their reasons meet the criteria for retraction.

Retractions are issued to correct the scholarly record and should not be interpreted as punishments for the authors.

The COPE guidance can be found [here](#).

Retractions will be considered in cases where:

- There is clear evidence that the findings are unreliable, either as a result of misconduct (e.g., data fabrication or image manipulation) or honest error (e.g., miscalculation or experimental error).
- The findings have previously been published elsewhere without proper referencing, permission, or justification (e.g., cases of redundant or duplicate publication).
- The research constitutes plagiarism.
- The Editor no longer has confidence in the validity or integrity of the article.
- There is evidence or concerns of authorship for sale.
- There is evidence of compromised peer review or systematic manipulation.
- There is evidence of unethical research, or there is evidence of a breach of editorial policies.
- The authors have deliberately submitted fraudulent or inaccurate information, or breached a warranty provided in the Author Publishing Agreement (APA).

Where the decision has been taken to retract an article, Dove Medical Press will:

- Add a "retracted" watermark to the final published version of the article.
- Issue a separate retraction statement, titled "[article title] [Retraction]", which will be linked to the retracted article on the Dove Medical Press website.
- Paginate and make available the retraction statement in the online issue of the journal.

References

- Committee on Publication Ethics Council. (2019, December 10). *Retraction guidelines*. Retrieved December 16, 2023 from <https://publicationethics.org/retraction-guidelines>
- Oransky, I. (2015, May 21). What should an ideal retraction notice look like? *Retraction Watch*. <https://retractionwatch.com/2015/05/21/what-should-an-ideal-retraction-notice-look-like/>
- Xu, S. B., & Hu, G. (2021). Retraction notices as a high-stakes academic genre: A move analysis. In K. L. Lin, I. N. Mwinlaaru, & D. Tay (Eds.), *Approaches to specialized genres* (pp. 101–120). Routledge. <https://doi.org/https://doi.org/10.4324/9780429053351>
- Xu, S. B., & Hu, G. (2023). What to communicate in retraction notices? *Learned Publishing*, 36(3), 463-467. <https://doi.org/10.1002/leap.1548>
- Xu, S. B., & Hu, G. (2024). Research retraction and its communication. In D. B. A. M. Khosrow-Pour (Ed.). IGI Global. <https://doi.org/10.4018/978-1-6684-7366-5.ch030>
<https://www.crossref.org/blog/news-crossref-and-retraction-watch/>
https://groups.niso.org/higherlogic/ws/public/download/29165/RP-45-202X_NISO_Communication_of_Retractions_Removals_and_Expressions_of_Concern_CREC_draft_for_public_comment.pdf
<https://www.dovepress.com/retraction-fabrication-and-characterization-of-glimepiride-nanosuspens-peer-reviewed-fulltext-article-IJN>
<https://www.dovepress.com/getfile.php?fileID=85704>
<https://www.dovepress.com/getfile.php?fileID=85705>
<https://www.dovepress.com/editorial-policies/corrections-retractions>